- During a press conference in Geneva this morning, Martin Velasco, Pascal Mock MD and Prof. Patrick Aebischer, President of the EPFL (Ecole Polytechnique Fédérale de Lausanne), presented a solution which opens promising new prospects in terms of assisted reproductive technology. - A major advantage of the ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary ...
Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals Announce World Class Partnership in State of the Art Cancer Therapy Dusseldorf (ots) - ION Boston Management GmbH, which is 50%-owned by Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals, has entered into a Radiology Oncology Associates ...
AC Immune, Ltd. enters into an Exclusive Global License Agreement and Research Collaboration with Genentech, Inc. for Development of Anti-beta-amyloid Antibodies for the Potential Treatment of Alzheimer's Disease and other human Diseases. Ecublens/Lausanne, Switzerland (ots) - AC Immune, Ltd., a Swiss Biotech Company developing innovative therapies against Alzheimer's Disease, today announced that it has entered into ...
Freising-Weihenstephan/Germany (ots) - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics Pieris AG, a biopharmaceutical company developing therapeutic products comprising Anticalins®, a novel ...
Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with pramipexole (Sifrol(R)/Mirapexin(R)), ...
Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...
Amsterdam (ots) - - New Pan-European Sociological Survey Announced by the European Parkinson's Disease Association (EPDA), Reveals the 'Hidden Face' of PD Over 80 percent of surveyed people with Parkinson's disease (PD) 'often' or 'sometimes' suffer from depressive symptoms as part ...
Aachen (ots) - Tapentadol would be the first new molecular entity in the class of oral centrally acting analgesics to enter medical practice in over 25 years. At the American Pain Society Meeting in San Antonio, Texas, Grünenthal GmbH presented positive results on preclinical and early clinical studies of ...
Mittelhäusern (ots) - MEDISTICK GmbH, a young Swiss company, has developed what they believe is the world's first personal multilingual medical record device. The innovative technical software solution on an UBS memory stick format helps to provide swift accurate medical diagnoses and treatments to everybody independent of their whereabouts or language skills. The encrypted software© program loaded on the memory ...
21st Annual Meeting of the European Association of Urology (EAU), Paris, 5th - 8th April 2006 Treatment with degarelix results in fast, profound and sustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge Paris (ots) - Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous ...
Gaithersburg, MD (ots) - Authors recommend demonstration projects to show how to best implement HPV testing as primary screen, followed by cytology An analysis of 11 European and North American studies involving more than 60'000 women, published in the April issue of the International Journal of ...
Lugano/Johannesburg (ots) - HELSINN HEALTHCARE SA, and PFIZER LABORATORIES (PTY) LTD, announce the signing of an agreement granting PFIZER in South Africa, the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by ...
Dreieich/Wolfsburg (ots) - The city of Wolfsburg is home to Volkswagen, the car makers. Its reputation to date has mainly been as a motor of progress in the development of modern production methods for the automotive industry. But Wolfsburg is now about to make a name for itself as a European pioneer in implementing better strategies for preventing cervical cancer. ...
Zurich (ots) - Baxter Healthcare S.A. announced today that Baxter"s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Once licensed, ...
ESOT - European Society for Organ Transp
Geneva (ots) - On behalf of our National Advisory and Local Organising Committees, we extend a warm invitation to you to join us in Switzerland for the 12th ESOT Congress 2005, 16-19 October, in Geneva. Our programme structure proposes the classical form of an international congress, including pre-congress workshops, free paper sessions and plenary sessions. ...
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...
Austrian Breast and Colorectal Cancer St
San Antonio, Texas (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
Austrian Breast and Colorectal Cancer St
San Antonio (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
During the first quarter, Unilabs laboratories achieved: - revenues of CHF 54.8 million (+4.7%) - EBITDA margin of CHF 6.2 million (+18.6%) - EBIT margin of CHF 4.1 million (+29.3%) Geneva (ots) - During the first quarter of the 2004/2005 fiscal year, which ended on 31 August 2004, Unilabs laboratories achieved consolidated revenues of CHF 54.8 million, up 4.7% as compared to the same prior year period, or 5.1% at ...
DEERFIELD, Ill., and CONCORD, Calif. (ots) - Subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The ...
Geneva (ots) - The Unilabs laboratory in Lugano (Tessin) has signed an agreement with two hospital establishments located in the Lugano area. These hospitals comprise a total of 150 beds and accommodate around 6,500 hospitalized patients and 32,000 outpatients per year. The contract, which takes effect immediately, relates to an estimated annual turnover of CHF 1.5 million and a minimum period of until December 31, ...
Geneva (ots) - Biocheckup tests will allow early detection of signs of illness and permit evaluation of the risk factors for diseases such as diabetes, cancer or cardiovascular disease Most people are concerned by the state of their health and would like to know their predisposition to different pathologies before they become established (e.g. diabetes, cancer, ...
Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...
Volketswil (ots) - JUVENA of Switzerland is the first cosmetics company world-wide to integrate technology from the field of emergency medicine into skin care products. The basis for this technology is the research work of Professor Odile Damour*, head of the Laboratoire des Substituts Cutanés in Lyon (FR) and authority in the field of biological skin ...
Volketswil (ots) - JUVENA of Switzerland is working side by side with a strong partner: Professor Odile Damour, an authority in the field of natural skin reconstruction. She heads the Laboratoire des Substituts Cutanés of the University of Lyon, one of the leading institutes for the healing of burn related injuries. JUVENA of Switzerland decided at the beginning of ...
London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...
Brussels, Belgium (ots) - Universite Louis Pasteur Strasbourg Invited to Demonstrate Health Hero Network Technology at 'The Contribution of ICT to Health' Ministerial Conference and Exhibition 22-23 May -- Brussels Health Hero Network, Ltd. was selected with Universite Louis Pasteur (ULP) Strasbourg to present its Health Buddy(R) in-home health monitoring ...